Medtronic receives FDA approval for InterStim X™ system, the next generation of the most personalized sacral nerve stimulation therapy for bladder and bowel control
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it received approval from the U.S. Food and Drug Administration (FDA) for InterStim X™ ― the next generation of the InterStim™ portfolio’s recharge-free device – and it is available immediately.

The whole article:
https://infomeddnews.com/medtronic-interstim-x-system-next-generation/